The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years
Open accessAbstract
OBJECTIVES: To report on a 10 year follow up of patients with idiopathic Parkinson's disease, particularly with respect to mortality and the effect of early treatment with bromocriptine. METHODS: The patients are from the 149 new patients recruited for a double blind, randomised study of low dose levodopa-carbidopa versus low dose bromocriptine. Patients were examined neurologically at least yearly. Neuropsychological examinations were performed at 0, 3, 5, and 10 years. Mortality and cause of death in these patients were compared with the Australian population using standardised mortality ratios (SMRs). Mortality and disease progression were compared by sex and treatment group. Predictors of death within 10 years, nursing home admission, and progression in Columbia score of >/=20 points were examined by logistic regression analysis. RESULTS: Thirteen patients were excluded as having atypical Parkinsonism and six were lost to follow up. All available patients have been followed up for 10 years. Fifty patients (38%) were dead by 10 years and 63 by the last follow up. The SMR was 1.58 for all patients (p<0. 001). There was no significant difference in SMRs between the sexes. The mean duration of disease until death was 9.1 years. Parkinson's disease was thought to have contributed substantially to the death of 30 patients. The most common cause of death was pneumonia. Women progressed at a similar rate to men until 8 years, when the severity of their disease as measured by Hoehn and Yahr stage became greater (p<0.05). Older age of onset correlated with increased risk of death but the SMR was increased even in those aged <70 years (SMR 1.80, p=0.03). Early use of bromocriptine did not reduce mortality or slow progression of disease. One quarter of all patients had been admitted to nursing homes by 10 years. Only four patients were still employed. CONCLUSIONS: Mortality in Parkinson's disease remains increased despite low dose levodopa-carbidopa therapy and no additional benefit was gained from early use of bromocriptine. Duration of disease was similar to that in the era before levodopa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Variable expression of Parkinson's disease: A base‐line analysis of the DAT ATOP cohort
Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., Huber, S., Koller, W., Olanow, C., Shoulson, I., et al. (1990) · Neurology · doi:10.1212/wnl.40.10.1529 · Cited by 1,285
Parkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,061
Epidemiology of parkinsonism: Incidence, classification, and mortality
Rajput, A. H., Offord, K. P., Beard, C. M., & Kurland, L. T. (1984) · Annals of Neurology · doi:10.1002/ana.410160303 · Cited by 340
The effect of deprenyl and levodopa on the progression of Parkinson's disease
Olanow, C. W., Hauser, R. A., Gauguster, L., Malapira, T., Koller, W., Hubble, J., Bushenbark, K., Lilienfeld, D., & Esterlitz, J. (1995) · Annals of Neurology · doi:10.1002/ana.410380512 · Cited by 334
Mortality and hallucinations in nursing home patients with advanced Parkinson's disease
Goetz, C. G., & Stebbins, G. T. (1995) · Neurology · doi:10.1212/wnl.45.4.669 · Cited by 287
A METHOD FOR EVALUATING DISABILITY IN PATIENTS WITH PARKINSONʼS DISEASE
CANTER, G. J., de La TORRE, R., & MIER, M. (1961) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196108000-00010 · Cited by 220
Young‐onset Parkinson's disease: A clinical review
Golbe, L. I. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.168 · Cited by 200
Morens, D. M., Davis, J. W., Grandinetti, A., Ross, G. W., Popper, J. S., & White, L. R. (1996) · Neurology · doi:10.1212/wnl.46.4.1044 · Cited by 184
Parkinson's disease and its comorbid disorders: An analysis of Michigan mortality data, 1970 to 1990
Gorell, J. M., Johnson, C. C., & Rybicki, B. A. (1994) · Neurology · doi:10.1212/wnl.44.10.1865 · Cited by 175
Mortality From Parkinson Disease
Louis, E. D., Marder, K., Cote, L., Tang, M., & Mayeux, R. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550150024011 · Cited by 165
Mortality in DATATOP: A Multicenter trial in early Parkinson's disease
Shoulson, & Parkinson Study Group (1998) · Annals of Neurology · doi:10.1002/ana.410430309 · Cited by 165
The Impact of Treatment with Levodopa on Parkinson's Disease
(1980) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a067623 · Cited by 164
Hely, M. A., Morris, J. G., Reid, W., O'Sullivan, D. J., Williamson, P. M., Rail, D., Broe, G. A., & Margrie, S. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.8.903 · Cited by 154
Self-citationMulti‐center study of Parkinson mortality with early versus later dopa treatment
Diamond, S. G., Marchkham, C. H., Hoehn, M. M. M., MCDOWELL, F. H., & Muenter, M. D. (1987) · Annals of Neurology · doi:10.1002/ana.410220105 · Cited by 150
Clinical observations on the rate of progression of idiopathic parkinsonism
Lee, C. S., Schulzer, M., Mak, E., Snow, B. J., Tsui, J. K. C., Clane, S., Hammerstad, J. P., & Clane, D. B. (1994) · Brain · doi:10.1093/brain/117.3.501 · Cited by 147
Rajput, A. H., Offord, K. P., Beard, C. M., & Kurland, L. T. (1987) · Neurology · doi:10.1212/wnl.37.2.226 · Cited by 144
Levodopa therapy and survival in idiopathic Parkinson's disease
Uitti, R. J., Ahlskog, J. E., Maraganore, D. M., Muenter, M. D., Atkinson, E. J., H., R., & O’Brien, P. C. (1993) · Neurology · doi:10.1212/wnl.43.10.1918 · Cited by 136
An examination of male‐female differences in progression and mortality of Parkinson's disease
Diamond, S. G., Markham, C. H., Hoehn, M. M. M., MCDOWELL, F. H., & Muenter, M. D. (1990) · Neurology · doi:10.1212/wnl.40.5.763 · Cited by 131
Six Years of High-Level Levodopa Therapy in Severely Akinetic Parkinsonian Patients
Barbeau, A. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500050019004 · Cited by 118
Clinical course of patients with idiopathic Parkinson's disease
Roos, R. A. C., Jongen, J. C. F., & van der Velde, E. A. (1996) · Movement Disorders · doi:10.1002/mds.870110304 · Cited by 112
The natural history of Parkinson's disease
Poewe, W. H., & Wenning, G. K. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.146s · Cited by 111
Low cancer rates among patients with Parkinson's disease
Jansson, B., & Jankovic, J. J. (1985) · Annals of Neurology · doi:10.1002/ana.410170514 · Cited by 101
Effect of physical exercise on mortality in patients with Parkinson's disease
Kuroda, K., Tatara, K., Takatorige, T., & Shinsho, F. (1992) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1992.tb08054.x · Cited by 98
Ben‐Shlomo, Y., Churchyard, A., Head, J. A., Hurwitz, B., Overstall, P. W., Ockelford, J., & Lees, A. J. (1998) · BMJ · doi:10.1136/bmj.316.7139.1191 · Cited by 95
Age at onset: the major determinant of outcome in Parkinson's disease
Hely, M. A., Morris, J. G., Reid, W., O'Sullivan, D. J., Williamson, P. M., Broe, G. A., & ADENA, M. A. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1995.tb00480.x · Cited by 88
Self-citationDoes levodopa therapy delay death in Parkinson's disease? A review of the evidence
Clarke, C. E. (1995) · Movement Disorders · doi:10.1002/mds.870100303 · Cited by 84
Mortality of patients with parkinson's disease treated with levodopa
Marttila, R. J., Rinne, U. K., Siirtola, T., & Sonninen, V. H. (1977) · Journal of Neurology · doi:10.1007/bf00313615 · Cited by 84
Mortality in patients with Parkinson's disease
Wermuth, L., Stenager, E., Stenager, E., & Boldsen, J. L. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1995.tb00466.x · Cited by 84
A longitudinal of Parkinson's disease: clinical and neuropsychological correlates of dementia
Reid, W. G. J., Hely, M. A., Morris, J. G., Broe, G. A., ADENA, M. A., Sullivan, D. J. O., & Williamson, P. M. (1996) · Journal of Clinical Neuroscience · doi:10.1016/s0967-5868(96)90028-4 · Cited by 78
Self-citationRisk factors for progression in Parkinson's disease
Goetz, C. G., Tanner, C. M., Stebbins, G. T., & Buchman, A. S. (1988) · Neurology · doi:10.1212/wnl.38.12.1841 · Cited by 78
Przuntek, H., Welzel, D., Blümner, E., Danielczyk, W., Letzel, H., Kaiser, H. J., Kraus, P. H., Riederer, P. F., Schwarzmann, D., Wolf, H., et al. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf02220609 · Cited by 65
Two Decades of Increasing Mortality From Parkinson's Disease Among the US Elderly
Lilienfeld, D. E., Chan, E., Ehland, J., Godbold, J., Landrigan, P. J., Marsh, G. M., & Perl, D. P. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530070019005 · Cited by 65
Mortality among Parkinson Patients Treated with L-Dopa Combined with a Decarboxylase Inhibitor
Zumstein, H., & Siegfried, J. (2008) · European Neurology · doi:10.1159/000114756 · Cited by 65
Levodopa in Parkinson disease: A long‐term appraisal of mortality
Joseph, C., Chassan, J. B., & Koch, M. (1978) · Annals of Neurology · doi:10.1002/ana.410030205 · Cited by 64
The changing patterns of death rates in parkinsonism
Kurtzke, J. F., & Murphy, F. M. (1990) · Neurology · doi:10.1212/wnl.40.1.42 · Cited by 62
Parkinson's disease in Aberdeen: survival after 3.5 years
Ebmeier, K. P., Calder, S. A., Crawford, J., Stewart, L., BESSON, J. A. O., & Mutch, W. J. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1990.tb01558.x · Cited by 60
EFFECT OF L-DOPA ON COURSE OF PARKINSON'S DISEASE
Curtis, L. D., Lees, A. J., Stern, G. M., & Marmot, M. G. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90493-8 · Cited by 54
Mortality from Parkinson's disease
Clarke, C. E. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.2.254 · Cited by 29
Parkinson's Disease Mortality in Italy, 1951 Through 1987
Chiò, A. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540020027012 · Cited by 19
AGING AND PARKINSONS-DISEASE - SUBSTANTIA-NIGRA REGIONAL SELECTIVITY
FEARNLEY, J., & LEES, A. (1991) · UCL Discovery (University College London) · Cited by 10
Cited by
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., Giladi, N., Holloway, R. G., Moore, C. G., Wenning, G. K., et al. (2004) · Movement Disorders · doi:10.1002/mds.20213 · Cited by 2,347
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
Self-citationThe Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Bloem, B. R., Hausdorff, J. M., Visser, J. E., & Giladi, N. (2004) · Movement Disorders · doi:10.1002/mds.20115 · Cited by 1,297
Metadata
- Authors
- Hely, M. A., Morris, J. G. L., Traficante, R., Reid, W. G. J., O'Sullivan, D. J., & Williamson, P. M.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 1999-09-01
- Volume
- 67
- Issue
- 3
- Pages
- 300-307
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2084388513
- Cited by
- 377
- References
- 44
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.